📰 Junshi Bioscience News
Page 9 - Junshi Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Junshi Bioscience. Real-time updates on events, politics, business and more.
October 15, 2021
/PRNewswire/ -- The "Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.coms offering. The...
October 14, 2021
Dublin, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030" report has been added to...
September 17, 2021
– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 – – Data support the use of...
September 17, 2021
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06 - read this article along with other careers information, tips and advice on BioSpace
September 17, 2021
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for
August 19, 2021
- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone - - Data support the use of toripalimab with chemotherapy as first-line
August 12, 2021
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA SHANGHAI, China and REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai
August 12, 2021
Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
August 12, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.